Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Clinical utility of serum autoantibodies detected by protein microarray in melanoma.

Sabel MS, Liu Y, Griffith KA, He J, Xie X, Lubman DM.

Int J Proteomics. 2011;2011:413742. doi: 10.1155/2011/413742. Epub 2011 Oct 19.

2.

Serum autoantibody profiling using a natural glycoprotein microarray for the prognosis of early melanoma.

Liu Y, He J, Xie X, Su G, Teitz-Tennenbaum S, Sabel MS, Lubman DM.

J Proteome Res. 2010 Nov 5;9(11):6044-51. doi: 10.1021/pr100856k. Epub 2010 Oct 20.

3.

Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model.

Sondak VK, Taylor JM, Sabel MS, Wang Y, Lowe L, Grover AC, Chang AE, Yahanda AM, Moon J, Johnson TM.

Ann Surg Oncol. 2004 Mar;11(3):247-58.

4.

The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma.

Paek SC, Griffith KA, Johnson TM, Sondak VK, Wong SL, Chang AE, Cimmino VM, Lowe L, Bradford CR, Rees RS, Sabel MS.

Cancer. 2007 Jan 1;109(1):100-8.

5.

A retrospective, multicenter analysis of the predictive value of mitotic rate for sentinel lymph node (SLN) positivity in thin melanomas.

Wat H, Senthilselvan A, Salopek TG.

J Am Acad Dermatol. 2016 Jan;74(1):94-101. doi: 10.1016/j.jaad.2015.09.014. Epub 2015 Nov 2.

PMID:
26542815
6.

Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy?

Mays MP, Martin RC, Burton A, Ginter B, Edwards MJ, Reintgen DS, Ross MI, Urist MM, Stromberg AJ, McMasters KM, Scoggins CR.

Cancer. 2010 Mar 15;116(6):1535-44. doi: 10.1002/cncr.24895.

7.

Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.

Niakosari F, Kahn HJ, McCready D, Ghazarian D, Rotstein LE, Marks A, Kiss A, From L.

Arch Dermatol. 2008 Apr;144(4):462-7. doi: 10.1001/archderm.144.4.462.

PMID:
18427039
8.

Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma.

Kruper LL, Spitz FR, Czerniecki BJ, Fraker DL, Blackwood-Chirchir A, Ming ME, Elder DE, Elenitsas R, Guerry D, Gimotty PA.

Cancer. 2006 Nov 15;107(10):2436-45.

9.

Sentinel lymph node dissection in stage I/II melanoma patients: surgical management and clinical follow-up study.

Macripò G, Quaglino P, Caliendo V, Ronco AM, Soltani S, Giacone E, Pau S, Fierro MT, Bernengo MG.

Melanoma Res. 2004 Apr;14(2):S9-12.

PMID:
15057050
10.

Sentinel lymph node biopsy for cutaneous melanoma: the Stanford experience, 1997-2004.

Berk DR, Johnson DL, Uzieblo A, Kiernan M, Swetter SM.

Arch Dermatol. 2005 Aug;141(8):1016-22.

PMID:
16103331
11.

Regression does not predict nodal metastasis or survival in patients with cutaneous melanoma.

Burton AL, Gilbert J, Farmer RW, Stromberg AJ, Hagendoorn L, Ross MI, Martin RC 2nd, McMasters KM, Scoggins CR, Callender GG.

Am Surg. 2011 Aug;77(8):1009-13.

PMID:
21944515
12.

Sentinel lymph node biopsy in melanoma patients with clinically negative regional lymph nodes--one institution's experience.

Nowecki ZI, Rutkowski P, Nasierowska-Guttmejer A, Ruka W.

Melanoma Res. 2003 Feb;13(1):35-43.

PMID:
12569283
13.

Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.

Taylor RC, Patel A, Panageas KS, Busam KJ, Brady MS.

J Clin Oncol. 2007 Mar 1;25(7):869-75.

PMID:
17327608
14.

The analysis of the outcomes and factors related to iliac-obturator involvement in cutaneous melanoma patients after lymph node dissection due to positive sentinel lymph node biopsy or clinically detected inguinal metastases.

Zdzienicki M, Rutkowski P, Nowecki ZI, van Akkooi AC, Michej W, Dziewirski W, Świtaj T, Pieńkowski A, Sałamacha M, Bylina E, Eggermont AM.

Eur J Surg Oncol. 2013 Mar;39(3):304-10. doi: 10.1016/j.ejso.2012.12.014. Epub 2013 Jan 5.

PMID:
23298828
15.

Sentinel Lymph Node Biopsy Use Among Melanoma Patients 75 Years of Age and Older.

Sabel MS, Kozminski D, Griffith K, Chang AE, Johnson TM, Wong S.

Ann Surg Oncol. 2015 Jul;22(7):2112-9. doi: 10.1245/s10434-015-4539-7. Epub 2015 Apr 3.

PMID:
25834993
16.

Is there a benefit to sentinel lymph node biopsy in patients with T4 melanoma?

Gajdos C, Griffith KA, Wong SL, Johnson TM, Chang AE, Cimmino VM, Lowe L, Bradford CR, Rees RS, Sabel MS.

Cancer. 2009 Dec 15;115(24):5752-60. doi: 10.1002/cncr.24660.

17.
18.

Sentinel lymph node biopsy for melanoma: experience with 234 consecutive procedures.

Wagner JD, Corbett L, Park HM, Davidson D, Coleman JJ, Havlik RJ, Hayes JT 2nd.

Plast Reconstr Surg. 2000 May;105(6):1956-66.

PMID:
10839392
19.

Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.

Mandalà M, Imberti GL, Piazzalunga D, Belfiglio M, Labianca R, Barberis M, Marchesi L, Poletti P, Bonomi L, Novellino L, Di Biagio K, Milesi A, Guerra U, Tondini C.

Eur J Cancer. 2009 Sep;45(14):2537-45. doi: 10.1016/j.ejca.2009.05.034. Epub 2009 Jun 22.

PMID:
19553103
20.

Significance of multiple nodal basin drainage in truncal melanoma patients undergoing sentinel lymph node biopsy.

Porter GA, Ross MI, Berman RS, Lee JE, Mansfield PF, Gershenwald JE.

Ann Surg Oncol. 2000 May;7(4):256-61.

PMID:
10819364

Supplemental Content

Support Center